

# Proposed Rules

Federal Register

Vol. 80, No. 174

Wednesday, September 9, 2015

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### 21 CFR Part 15

[Docket No. FDA-2015-N-0540]

#### Homeopathic Product Regulation: Evaluating the Food and Drug Administration's Regulatory Framework After a Quarter-Century; Reopening of the Comment Period

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public hearing; reopening of the comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is reopening the comment period for the notice of public hearing that appeared in the **Federal Register** of March 27, 2015. In the notice of public hearing, FDA requested comments on a number of specific questions identified in the document. The Agency is taking this action in response to requests to allow interested persons additional time to submit comments.

**DATES:** FDA is reopening the comment period on the notice of public hearing published March 27, 2015 (80 FR 16327), and extended on June 10, 2015 (80 FR 32868). Submit either electronic or written comments by November 9, 2015.

**ADDRESSES:** You may submit comments by any of the following methods:

#### Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.

#### Written Submissions

Submit written submissions in the following ways:

- *Mail/Hand delivery/Courier (for paper submissions):* Division of Dockets Management (HFA-305), Food and Drug

Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

**Instructions:** All submissions received must include the Docket No. FDA-2015-N-0540 for this notice of public hearing. All comments received may be posted without change to <http://www.regulations.gov>, including any personal information provided. For additional information on submitting comments, see the "Request for Comments" heading of the **SUPPLEMENTARY INFORMATION** section of this document.

**Docket:** For access to the docket to read background documents or comments received, go to <http://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

#### FOR FURTHER INFORMATION CONTACT:

Elaine Lippmann, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6214, Silver Spring, MD 20993-0002, 301-796-2895.

#### SUPPLEMENTARY INFORMATION:

##### I. Background

In the **Federal Register** of March 27, 2015, FDA published a notice of public hearing with a 60-day comment period following the public hearing and requested comments on a number of specific questions identified throughout the document. Comments on the notice of public hearing will inform FDA's decision about whether and how to adjust the current enforcement policies for drug products labeled as homeopathic to reflect changes in the homeopathic product marketplace over the last approximately 25 years. In the **Federal Register** of June 10, 2015, in response to requests for an extension to allow interested persons additional time to submit comments, FDA extended the original comment period for 60 days, until August 21, 2015.

FDA is reopening the comment period for an additional 60 days, until November 9, 2015. The Agency believes that reopening the comment period for an additional 60 days for the notice of public hearing will allow adequate time for interested persons to submit comments without significantly

delaying Agency decisionmaking on these important issues.

## II. Request for Comments

Interested persons may submit either electronic comments regarding this document to <http://www.regulations.gov> or written comments to the Division of Dockets Management (see **ADDRESSES**). You should annotate and organize your comments to identify the specific questions or topic to which they refer. It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at <http://www.regulations.gov>.

Dated: September 3, 2015.

**Leslie Kux,**

*Associate Commissioner for Policy.*

[FR Doc. 2015-22682 Filed 9-8-15; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF STATE

### 22 CFR Part 171

[Public Notice: 9263]

RIN 1400-AD78

#### Privacy Act; STATE-75, Family Advocacy Case Records

**AGENCY:** Department of State.

**ACTION:** Notice of proposed rulemaking.

**SUMMARY:** The Department of State is giving notice that certain portions of the Family Advocacy Case Records, STATE-75, system of records are proposed to be exempt from one or more provisions of the Privacy Act of 1974.

**DATES:** Comments on this rule are due by October 19, 2015.

**FOR FURTHER INFORMATION CONTACT:** John Hackett, Director; Office of Information Programs and Services, A/GIS/IPS; Department of State, SA-2; 515 22nd Street NW., Washington, DC 20522-8001, or at [Privacy@state.gov](mailto:Privacy@state.gov).

**SUPPLEMENTARY INFORMATION:** The Department of State maintains the Family Advocacy Case Records system of records. The primary purpose of this system of records is to be utilized at post by members of the Family Advocacy Team and in the Department